Feyi Ayodele

Bio

Feyi Olopade Ayodele is CancerIQ’s co-founder and CEO. In this role, Feyi is leading CancerIQ’s bold vision to end cancer as we know it by empowering providers and health systems to expand access to precision cancer prevention, early detection & treatment. CancerIQ makes it easy for health systems to use genetic information to get ahead of cancer at scale. Its best-in-class, science-based platform is proven to double genetic counseling service capacity, quadruple genetic testing uptake & significantly improve screening compliance.
 

Under Feyi’s leadership, CancerIQ has grown its provider network to over 200 locations across the county and established a robust ecosystem of leading diagnostic, genomics testing, telehealth, and AI vendors. These efforts have enabled health systems to increase the use of preventive services, generate downstream revenue, improve quality and screening compliance, and shift cancer diagnoses to earlier stages. Concurrently, CancerIQ has helped its life sciences partners get their innovative, life-saving technologies into the hands of more providers.
 

Most recently, Feyi was named a Modern Healthcare Innovator for 2024 and saw CancerIQ listed among the world’s best digital health companies by Newsweek. A trusted expert in the field of precision prevention, Feyi is routinely featured by prominent industry outlets and organizations including HLTH Matters, Forbes, TechCrunch, Health Management Academy, the Association of Cancer Executives, and more.
 

In recognition of her success, Feyi was named to Crain’s Chicago Business 40 under 40 list in 2019 and has won multiple honors including a Chicago Innovation Award, the Chicago Booth New Venture Challenge, a fellowship from Rock health, and the Women Tech Founders Award. In 2022, Feyi closed CancerIQ’s Series B funding round, led by Merck Global Health Innovation Fund and Amgen Ventures, making her one of the most-funded Black female founders of the year.
 

Feyi received both her bachelor’s and MBA from The Wharton School. Prior to CancerIQ, she worked as a management consultant, investor, and investment banker at McKinsey, Actis LLP, and Credit Suisse, respectively.